KKR Completes Block Trade of Shares in BridgeBio Pharma
02.19.21
This is only gets display when printing
Simpson Thacher represented KKR in connection with the sale of 3,450,000 shares of BridgeBio Pharma, Inc. The secondary offering, which was effected pursuant to a block trade, raised gross sale proceeds of approximately $208.6 million. The transaction closed on February 17, 2021.
BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio’s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.
The Simpson Thacher team included Richard Fenyes and Nicholas Halliburton (Capital Markets); and James Rapp (Public Company Advisory Practice).